The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
Open accessAbstract
This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines, Cervarix (GlaxoSmithKline) and Gardasil (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n = 1106) were stratified by age (18-26, 27-35, 36-45 years) and randomized (1:1) to receive Cervarix (Months 0, 1, 6) or Gardasil (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum neutralizing antibodies, as measured by pseudovirion-based neutralization assay (PBNA), except for two women aged 27-35 years in the Gardasil group who did not seroconvert for HPV-18 (98%). Geometric mean titers of serum neutralizing antibodies ranged from 2.3-4.8-fold higher for HPV-16 and 6.8-9.1-fold higher for HPV-18 after vaccination with Cervarix compared with Gardasil, across all age strata. In the total vaccinated cohort (all women who received at least one vaccine dose, regardless of their serological and DNA status prior to vaccination), Cervarix induced significantly higher serum neutralizing antibody titers in all age strata (p < 0.0001). Positivity rates for anti-HPV-16 and -18 neutralizing antibodies in cervicovaginal secretions and circulating HPV-16 and -18 specific memory B-cell frequencies were also higher after vaccination with Cervarix compared with Gardasil. Both vaccines were generally well tolerated. The incidence of unsolicited adverse events was comparable between vaccinated groups. The incidence of solicited symptoms was generally higher after Cervarix, injection site reactions being most common. However, compliance rates with the three-dose schedules were similarly high (>or= 84%) for both vaccines. Although the importance of differences in magnitude of immune response between these vaccines is unknown, they may represent determinants of duration of protection against HPV-16/18. Long-term studies evaluating duration of efficacy after vaccination are needed for both vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,538
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Human papillomavirus and cervical cancer
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61416-0 · Cited by 2,985
Smith, J. S., Lindsay, L., Hoots, B., Keys, J., Franceschi, S., Winer, R., & Clifford, G. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22527 · Cited by 1,686
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Self-citationHarper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
Self-citationVilla, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Innate immune sensing and its roots: the story of endotoxin
Beutler, B., & Rietschel, E. T. (2003) · Nature Reviews Immunology · doi:10.1038/nri1004 · Cited by 1,391
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
Self-citationMaintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304
Humoral Immunity Due to Long-Lived Plasma Cells
Slifka, M. K., Antia, R., Whitmire, J. K., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80541-5 · Cited by 1,245
McCredie, M. R., Sharples, K. J., Paul, C., Baranyai, J., Medley, G., Jones, R. W., & Skegg, D. C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70103-7 · Cited by 1,123
Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603469 · Cited by 806
Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B., & Schlegel, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11553 · Cited by 668
Breitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J. T., & Lowy, D. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3959-3963.1995 · Cited by 589
GIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
Self-citationGlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system
Crotty, S., Aubert, R. D., Glidewell, J., & Ahmed, R. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2003.12.015 · Cited by 421
Pastrana, D. V., Buck, C. B., Pang, Y.-Y. S., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Krüger Kjaer, S., Lowy, D. R., & Schiller, J. T. (2004) · Virology · doi:10.1016/j.virol.2003.12.027 · Cited by 357
Quadrivalent Human Papillomavirus Vaccine
Gellin, B., Modlin, J. F., Barr, E., & Tamms, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520654 · Cited by 330
Virus-like Particles of Bovine Papillomavirus Type 4 in Prophylactic and Therapeutic Immunization
KIRNBAUER, R., CHANDRACHUD, L. M., O'NEIL, B. W., WAGNER, E. R., GRINDLAY, G. J., ARMSTRONG, A., McGARVIE, G. M., SCHILLER, J. T., LOWY, D. R., & CAMPO, M. S. (1996) · Virology · doi:10.1006/viro.1996.0220 · Cited by 313
Opalka, D., Lachman, C. E., MacMullen, S. A., Jansen, K. U., Smith, J. F., Chirmule, N., & Esser, M. T. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.1.108-115.2003 · Cited by 276
Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms
Stanley, M., Lowy, D. R., & Frazer, I. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.110 · Cited by 262
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., Decarvalho, N. S., et al. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000154423.27940.68 · Cited by 247
Self-citationHepatitis A booster vaccination: is there a need?
Van Damme, P., Banatvala, J., Fay, O., Iwarson, S., McMahon, B., Van Herck, K., Shouval, D., Bonanni, P., Connor, B., Cooksley, G., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14418-2 · Cited by 238
(How) do aluminium adjuvants work?
BREWER, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2005.08.002 · Cited by 236
Barr, E., & Koutsky, L. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh071 · Cited by 230
Christensen, N. D., Reed, C. A., Cladel, N. M., Han, R., & Kreider, J. W. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.960-965.1996 · Cited by 220
Efficacy and other milestones for human papillomavirus vaccine introduction
Pagliusi, S. R., & Aguado, M. T. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.046 · Cited by 216
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory
Banatvala, J., Van Damme, P., & Oehen, S. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00224-3 · Cited by 213
Hepatitis B vaccine – do we need boosters?
Banatvala, J. E., & Van Damme, P. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00400.x · Cited by 207
Rambout, L., Hopkins, L., Hutton, B., & Fergusson, D. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.070948 · Cited by 187
Dessy, F. J., Giannini, S. L., Bougelet, C. A., Kemp, T. J., David, M.-P. M., Poncelet, S. M., Pinto, L. A., & Wettendorff, M. A. (2008) · Human Vaccines · doi:10.4161/hv.4.6.6912 · Cited by 179
Self-citationLong-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants
FitzSimons, D., François, G., Hall, A., McMahon, B., Meheus, A., Zanetti, A., Duval, B., Jilg, W., Böcher, W. O., Lu, S.-N., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.03.017 · Cited by 178
Jansen, K. U., Rosolowsky, M., Schultz, L. D., Markus, H. Z., Cook, J. C., Donnelly, J. J., Martinez, D., Ellis, R. W., & Shaw, A. R. (1995) · Vaccine · doi:10.1016/0264-410x(95)00103-8 · Cited by 164
Schwarz, T. F., Spaczyński, M., Schneider, A., Wysocki, J., Gałaj, A., Perona, P., Poncelet, S. M., Zahaf, T., Hardt, K., Descamps, D., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.088 · Cited by 152
Self-citationAlphs, H. H., Gambhira, R., Karanam, B., Roberts, J. N., Jagu, S., Schiller, J. T., Zeng, W., Jackson, D. C., & Roden, R. B. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800868105 · Cited by 150
Lin, Y., Borenstein, L. A., Selvakumar, R., et al. (1992) · Virology · doi:10.1016/0042-6822(92)90463-y · Cited by 149
Antigen dependent and independent mechanisms that sustain serum antibody levels
Traggiai, E., Puzone, R., & Lanzavecchia, A. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00198-1 · Cited by 143
Human papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
A review of the long-term protection after hepatitis A and B vaccination
Damme, P. V., & Herck, K. V. (2006) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2006.04.004 · Cited by 140
Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil??)
Siddiqui, M. A. A., & Perry, C. M. (2006) · Drugs · doi:10.2165/00003495-200666090-00008 · Cited by 137
Schwarz, T. F., & Léo, O. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.05.036 · Cited by 116
Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]
Keam, S. J., & Harper, D. M. (2008) · Drugs · doi:10.2165/00003495-200868030-00007 · Cited by 107
Viscidi, R. P., Snyder, B. S., Cu‐Uvin, S., Hogan, J. W., Clayman, B., Klein, R. S., Sobel, J. D., & Shah, K. V. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.283.14.1 · Cited by 93
Kemp, T. J., García‐Piñeres, A., Falk, R. T., Poncelet, S. M., Dessy, F. J., Giannini, S. L., Rodríguez, A. C., Porras, C., Herrero, R., Hildesheim, A., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.074 · Cited by 90
Self-citationPalker, T. J., Monteiro, J. M., Martin, M. M., Kakareka, C., Smith, J. F., Cook, J. C., Joyce, J. G., & Jansen, K. U. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00093-7 · Cited by 58
Smith, J. F., Kowalski, R., Esser, M. T., Brown, M. J., & Bryan, J. T. (2008) · Human Vaccines · doi:10.4161/hv.4.2.5261 · Cited by 56
Cederna, J. B., Klinzman, D., & Stapleton, J. T. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00342-4 · Cited by 55
Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine
Villa, L. L. (2007) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(07)60017-4 · Cited by 54
Human papillomavirus vaccines launch a new era in cervical cancer prevention
Dawar, M., Deeks, S. L., & Dobson, S. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.070771 · Cited by 45
Garçon, N., Mechelen, M. V., & Wettendorff, M. A. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50011-3 · Cited by 35
Crosbie, E. J., & Kitchener, H. C. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.391 · Cited by 35
Harper, D. M. (2008) · Therapy · doi:10.2217/14750708.5.3.313 · Cited by 15
Schwarz, T. F. (2007) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.2.3.293 · Cited by 11
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Immunological mechanisms of vaccination
Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
New adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Metadata
- Authors
- Einstein, M. H., Baron, M., Levin, M. J., Chatterjee, A., Edwards, R. P., Zepp, F., Carletti, I., Dessy, F. J., Trofa, A. F., Schuind, A., & Dubin, G.
- Venue
- Human Vaccines
- Publisher
- Informa UK Limited
- Published
- 2009-10
- Volume
- 5
- Issue
- 10
- Pages
- 705-719
- ISSN
- 1554-8600 (ISSN-L)
- 1554-8619
- OpenAlex
- W2114391710
- Cited by
- 402
- References
- 58
- FWCI
- 26.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.